VP 001
Alternative Names: VP-001Latest Information Update: 17 Jun 2024
At a glance
- Originator Lions Eye Institute; PYC Therapeutics
- Developer Vision Pharma
- Class Antisense oligonucleotides; Eye disorder therapies; Morpholines; Peptide drug conjugates
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Retinitis pigmentosa
Most Recent Events
- 12 Jun 2024 PYC Therapeutics plans a phase I trial for Retinal dystrophy in the US (IV) (NCT06455826)
- 11 Aug 2023 VP 001 receives Fast Track designation for Retinitis pigmentosa [Intravitreous,Injection] in USA
- 20 Apr 2023 Phase-I clinical trials in Retinitis pigmentosa in USA (Intravitreous) (NCT05902962)